Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Amgen Provides Ambitious Update On Biosimilars Business
CEO Says Company Expects To Double Biosimilar Revenues To Around $4bn By 2030
Jan 17 2022
•
By
Chloe Kent
Amgen has restated its ambitions to double the value of its biosimilars business by 2030 • Source: Alamy
More from Biosimilars
More from Products
